MARKET

VRAY

VRAY

ViewRay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.310
-0.220
-6.23%
After Hours: 3.320 +0.01 +0.30% 16:47 08/11 EDT
OPEN
3.530
PREV CLOSE
3.530
HIGH
3.610
LOW
3.270
VOLUME
1.74M
TURNOVER
--
52 WEEK HIGH
4.880
52 WEEK LOW
1.106
MARKET CAP
489.70M
P/E (TTM)
-3.7562
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VRAY stock price target is 3.042 with a high estimate of 4.000 and a low estimate of 2.000.

EPS

VRAY News

More
Kaohsiung Medical University Chung-Ho Memorial Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
ViewRay, Inc. (Nasdaq: VRAY) announced today that Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) in Kaohsiung City, Taiwan has begun patient treatments with the MRIdian® MR-Guided Radiation Therapy System, a cutting-edge device that delivers pe
PR Newswire · 6d ago
ViewRay's (VRAY) CEO Scott Drake on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 08/01 05:08
ViewRay, Inc. 2020 Q2 - Results - Earnings Call Presentation
Seeking Alpha · 07/31 19:15
ViewRay high post Q2 earnings
Seeking Alpha · 07/31 18:46
ViewRay, Inc. (VRAY) Q2 2020 Earnings Call Transcript
Image source: The Motley Fool. ViewRay, Inc. (NASDAQ: VRAY)Q2 2020 Earnings CallJul 30, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by, and welc
Motley Fool · 07/31 14:01
ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates
ViewRay (VRAY) delivered earnings and revenue surprises of -12.50% and 144.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 23:00
ViewRay shares are trading higher after the company reported Q2 earnings results.
Benzinga · 07/30 20:43
ViewRay Q2 EPS $(0.18) Misses $(0.16) Estimate, Sales $14.20M May Not Compare To $6.83M Estimate
ViewRay (NASDAQ:VRAY) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 43.75 percent increase over losses of $(0.32) per share from the same
Benzinga · 07/30 20:14

Industry

Advanced Medical Equipment & Technology
-0.81%
Healthcare Equipment & Supplies
-0.72%

Hot Stocks

Symbol
Price
%Change

About VRAY

ViewRay Inc. designs, manufactures and markets the ViewRay MRIdian. The MRIdian is a system that integrates high quality radiation therapy with simultaneous magnetic resonance imaging (MRI). It provides two generations of the MRIdian: the first generation MRIdian with Cobalt-60 based radiation beams and the second generation MRIdian Linac, with linear accelerator (linac) based radiation beams. The MRIdian combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients. MRIdian also records the level of radiation dose that the treatment area has received. MRIdian system is comprised of three components: the MRI system, the radiation delivery system and an integrated treatment planning and delivery software. The MRI system is the component of MRIdian that captures soft tissue images of the patient’s body. Its MRI system captures and displays live images in one plane, four times per second or in three planes, two times per second.
More

Webull offers kinds of Viewray Inc stock information, including NASDAQ:VRAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRAY stock methods without spending real money on the virtual paper trading platform.